Miracor Medical SA
Miracor Medical SA is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Miracor Medical SA.
Miracor Medical SA is a company.
Key people at Miracor Medical SA.
Key people at Miracor Medical SA.
Miracor Medical SA is a European medical device company based in Awans, Belgium, focused on developing innovative therapies for patients with impaired cardiac function, particularly those suffering from acute myocardial infarction (AMI) and heart failure.[1][2][3] The company builds the PiCSO® Impulse System, a pressure-controlled intermittent coronary sinus occlusion technology used as an adjunct to primary percutaneous coronary intervention (PCI) to improve coronary microvascular function, reduce infarct size, salvage myocardium, and potentially lower heart failure risk.[1][2][4] It serves cardiologists and heart teams treating severe cardiac diseases, addressing unmet needs in AMI by enhancing microcirculation viability through debris washout and blood flow redistribution to the peri-infarct zone.[3][4] With over $92M in total funding across six rounds (including $28.4M most recently) from investors like Molten Ventures, Capricorn Partners, Noshaq, Earlybird Venture Capital, and Quest for Growth, Miracor shows strong growth momentum, evidenced by ongoing randomized trials like PiCSO-AMI-I (144 patients in Europe) and the FDA IDE-approved PiCSO-AMI-II (300 patients in the US for anterior STEMI).[1][2][4]
Founded in 2008 in Awans, Belgium, Miracor Medical SA emerged to tackle limitations in AMI treatments by innovating coronary sinus interventions.[1][2] The company has accumulated over 150 years of collective medtech experience among its team, with a proven track record in cardiovascular devices, though specific founders are not detailed in available sources.[6] The core idea for the PiCSO® Impulse System stemmed from recognizing microvascular obstruction as a key barrier post-PCI; early development focused on this adjunctive therapy to boost myocardial salvage.[3] Pivotal moments include CE-marking the device, treating over 300 patients by 2022, launching the PICSO-AMI-V study for expanded indications, and securing FDA IDE approval in 2022 for the US pivotal trial—signaling clinical validation and global ambitions.[2][4]
Miracor rides the wave of interventional cardiology advancements, targeting microvascular dysfunction in AMI—a persistent challenge despite restored epicardial flow via stents, which affects up to 50% of STEMI cases and drives heart failure.[4] Timing aligns with rising AMI incidence, post-PCI innovation gaps, and regenerative heart therapies; market forces like aging populations, PCI volume growth, and demand for infarct-sparing tech favor it.[3] By validating PiCSO in large RCTs and expanding to heart failure, Miracor influences the ecosystem, offering heart teams novel adjuncts that could cut heart failure rates, lower costs, and inspire similar microcirculation-focused devices.[2][3]
Miracor's trajectory hinges on pivotal trial success: positive PiCSO-AMI-II results could unlock US approval, commercialization, and partnerships, while European post-market data supports relaunch.[4][5] Trends like AI-guided PCI, combo therapies, and heart failure reversals will shape it, potentially evolving PiCSO into a platform for chronic indications. Expect influence growth via adoption in high-volume cath labs, reducing global AMI burdens—if trials confirm safety/efficacy, it cements Miracor as a cardio medtech leader, fulfilling its mission to restore normal life for heart patients.[3]
